We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Snibe Co.,Ltd.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a global leader in the IVD field, with 30 years o... read more Featured Products: More products

Download Mobile App





SNIBE Brings Latest Innovations in Immunoassay, Clinical Biochemistry and Molecular Diagnostics to Medlab Middle East 2023

By LabMedica International staff writers
Posted on 09 Feb 2023

SNIBE (Shenzhen, China) is bringing its latest innovations, including new members from its product lines in immunoassay, clinical biochemistry and molecular diagnostics to Medlab Middle East 2023. More...

At Medlab Middle East 2023, SNIBE is showcasing Biolumi CX8, the new lab booster that combines one of the fastest immunoassay system MAGLUMI X8, and the biochemical system Biossays C8, with ultra-high throughput in a very small footprint. Moreover, it can also be customized according to specific needs, supporting up to four connected instruments, and covering the requirements of different laboratories. SNIBE is also showcasing the MAGLUMI X6 flexible CLIA solution that is designed for medium/high-volume laboratories. The MAGLUMI X6 offers flexible configuration modules and features new generation hydraulic TIP pipetting technology. It has a high speed of 450 tests/hour and is suitable for 155 chemiluminescence immunoreagents.

In addition, SNIBE is highlighting the Molecision S6 automated, integrated digital PCR system that provides a full-platform solution for research/in vitro diagnostics. Molecision S6 uses a cutting-edge cartridge that provides uniform droplets and prevents contamination, maximizing operation productivity and cost efficiency. Light oil is pre-filled in the cartridge so that the droplets can be sunk under the light oil to ensure a fully enclosed condition, achieving a sensitivity of 0.002%. Its highly integrated design and optimized system make it space-saving and easy to use. Alongside the Molecision S6, SNIBE is highlighting the Molecision MP-32 and MP-96 fully-auto nucleic acid purification systems that adopt a high-performance magnetic extraction method, thereby maximizing the recovery rate and consistency of results.

Related Links:
SNIBE


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Automated Clinical Chemistry Analyzer
Envoy 500+
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.